Education
About Us
Working with TipRanks
Follow Us
Basilea Pharmaceutica (CH:BSLN)
:BSLN
BSLN Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF34.55 - CHF48.25
Previous CloseN/A
Volume30.09K
Average Volume (3M)N/A
Market Cap
CHF552.36M
Enterprise ValueN/A
Total Cash (Recent Filing)CHF12.49M
Total Debt (Recent Filing)CHF128.61M
Price to Earnings (P/E)7.2
Beta0.75
Next Earnings
Aug 19, 2025EPS Estimate
1.39Last Dividend Ex-Date
Apr 11, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)6.40
Shares Outstanding13,172,048
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF84.50Price Target Upside75.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Market ExclusivityMarket exclusivity of Cresemba was extended to October 2027 in the EU and September 2027 in the U.S., providing flexibility for transition to a follow-up antifungal drug.
Regulatory ApprovalThe FDA approved Zevtera for treatment of severe acute bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP), representing a broad label.
Bears Say
Risks And SetbacksRisks include inability by Basilea's partners to optimize the value of isavuconazole and ceftobiprole globally and potential setbacks with clinical-stage candidates.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.05% Mutual Funds
0.11% Other Institutional Investors
91.52% Public Companies and
Individual Investors
BSLN FAQ
What was Basilea Pharmaceutica’s price range in the past 12 months?
Basilea Pharmaceutica lowest stock price was CHF34.55 and its highest was CHF48.25 in the past 12 months.
What is Basilea Pharmaceutica’s market cap?
Basilea Pharmaceutica’s market cap is CHF552.36M.
When is Basilea Pharmaceutica’s upcoming earnings report date?
Basilea Pharmaceutica’s upcoming earnings report date is Aug 19, 2025 which is in 159 days.
How were Basilea Pharmaceutica’s earnings last quarter?
Basilea Pharmaceutica released its earnings results on Feb 18, 2025. The company reported CHF3.24 earnings per share for the quarter, the consensus estimate of CHF3.24 by CHF0.
Is Basilea Pharmaceutica overvalued?
According to Wall Street analysts Basilea Pharmaceutica’s price is currently Undervalued.
Does Basilea Pharmaceutica pay dividends?
Basilea Pharmaceutica pays a Notavailable dividend of CHF5 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here
What is Basilea Pharmaceutica’s EPS estimate?
Basilea Pharmaceutica’s EPS estimate is 1.39.
How many shares outstanding does Basilea Pharmaceutica have?
Basilea Pharmaceutica has 13,172,048 shares outstanding.
What happened to Basilea Pharmaceutica’s price movement after its last earnings report?
Basilea Pharmaceutica reported an EPS of CHF3.24 in its last earnings report, expectations of CHF3.24. Following the earnings report the stock price went up 8.323%.
Which hedge fund is a major shareholder of Basilea Pharmaceutica?
Currently, no hedge funds are holding shares in CH:BSLN
---
BSLN Stock 12 Month Forecast
Average Price Target
CHF84.50
▲(75.49% Upside)
Best Analysts Covering BSLN
1 Year
1 Year Success Rate
10/12 ratings generated profit
1 Year Average Return
+7.32%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +7.32% per trade.
---